we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.
Company profile
Ticker
VTYX
Exchange
Website
CEO
Raju S. Mohan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Oppilan Pharma, Ltd. • Zomagen Biosciences Belgium BV • Zomagen Biosciences Ltd. ...
IRS number
832996852
VTYX stock data
Latest filings (excl ownership)
S-3
Shelf registration
9 Apr 24
8-K
Departure of Directors or Certain Officers
5 Apr 24
8-K
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides
11 Mar 24
8-K
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
7 Mar 24
POS AM
Prospectus update (post-effective amendment)
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
27 Feb 24
POSASR
Automatic shelf registration (post-effective amendment)
13 Feb 24
S-8
Registration of securities for employees
2 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
7 Dec 23
Transcripts
VTYX
Earnings call transcript
2023 Q2
13 Aug 23
VTYX
Earnings call transcript
2023 Q2
10 Aug 23
VTYX
Earnings call transcript
2023 Q1
11 May 23
VTYX
Earnings call transcript
2022 Q4
24 Mar 23
VTYX
Earnings call transcript
2022 Q3
6 Nov 22
VTYX
Earnings call transcript
2022 Q2
16 Aug 22
VTYX
Earnings call transcript
2022 Q1
13 May 22
Latest ownership filings
4
Somu Subramaniam
16 Apr 24
4
Change in insider ownership
16 Apr 24
SC 13G
Flynn James E
4 Apr 24
4
Christopher W Krueger
3 Apr 24
4
John Nuss
3 Apr 24
4
Raju Mohan
3 Apr 24
4
Martin Auster
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.59 mm | 57.59 mm | 57.59 mm | 57.59 mm | 57.59 mm | 57.59 mm |
Cash burn (monthly) | (no burn) | 17.14 mm | 19.32 mm | 16.35 mm | 11.55 mm | 13.51 mm |
Cash used (since last report) | n/a | 117.70 mm | 132.64 mm | 112.28 mm | 79.34 mm | 92.77 mm |
Cash remaining | n/a | -60.11 mm | -75.06 mm | -54.69 mm | -21.76 mm | -35.19 mm |
Runway (months of cash) | n/a | -3.5 | -3.9 | -3.3 | -1.9 | -2.6 |
Institutional ownership, Q2 2023
90.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 153 |
Opened positions | 29 |
Closed positions | 22 |
Increased positions | 70 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 1.73 tn |
Total shares | 63.98 mm |
Total puts | 958.50 k |
Total calls | 208.80 k |
Total put/call ratio | 4.6 |
Largest owners | Shares | Value |
---|---|---|
FMR | 8.55 mm | $280.55 bn |
NSV Investments I | 8.51 mm | $243.36 mm |
T. Rowe Price | 3.95 mm | $129.61 bn |
BLK Blackrock | 3.23 mm | $105.83 bn |
Citadel Advisors | 2.79 mm | $91.42 bn |
Capital International Investors | 2.73 mm | $89.47 bn |
venBio Global Strategic Fund III | 2.72 mm | $112.81 mm |
Vanguard | 2.38 mm | $78.22 bn |
Lord, Abbett & Co. | 2.32 mm | $76.04 bn |
JHG Janus Henderson | 1.77 mm | $57.93 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | NSV Partners III | Common Stock | Other | Dispose J | Yes | No | 0 | 695,339 | 0.00 | 7,744,296 |
12 Apr 24 | Somu Subramaniam | Common Stock | Other | Dispose J | Yes | No | 0 | 695,339 | 0.00 | 7,744,296 |
2 Apr 24 | Martin Auster | Common Stock | Sell | Dispose S | No | No | 5.4035 | 1,405 | 7.59 k | 24,303 |
2 Apr 24 | Raju Mohan | Common Stock | Sell | Dispose S | No | No | 5.4034 | 4,312 | 23.30 k | 1,578,250 |
2 Apr 24 | John Nuss | Common Stock | Sell | Dispose S | No | No | 5.4034 | 1,651 | 8.92 k | 264,998 |
News
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
5 Apr 24
Canaccord Genuity Maintains Buy on Ventyx Biosciences, Lowers Price Target to $15
13 Mar 24
Wells Fargo Upgrades Ventyx Biosciences to Overweight, Raises Price Target to $16
12 Mar 24
Oppenheimer Upgrades Ventyx Biosciences to Outperform, Announces $12 Price Target
12 Mar 24
Dow Turns Higher; GDS Holdings Shares Climb
11 Mar 24
Press releases
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences
25 Apr 24
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
25 Apr 24
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX
24 Apr 24
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
23 Apr 24